✦ LIBER ✦

EGFR mutations in patients with non-small cell lung cancer (NSCLC) and correlation with sensitivity to erlotinib

✍ Scribed by S. Ricciardi; B. Tedesco; M.R. Migliorino; P. Graziano; A. Leone; M. Di Salvia; V. Capodaglio; S. Condò; S. De Santis; F. De Marinis

Book ID: 119233688
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 63 KB
Volume: 6
Category: Article
ISSN: 1359-6349
DOI: 10.1016/j.ejcsup.2008.06.065

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Monitoring reversible and irreversible E

Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PET

✍ Scheffler, Matthias; Kobe, Carsten; Zander, Thomas; Nogova, Lucia; Kahraman, Den 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 510 KB

PD-157 Serum EGFR in patients with non-s

PD-157 Serum EGFR in patients with non-small cell lung cancer(NSCLC) treated with gefitinib

✍ Spreafico, A.; Gregorc, V.; Ludovini, V.; Pistola, L.; Amoroso, M.; Tofanetti, F 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 149 KB

Erlotinib as first-line treatment of Eur

Erlotinib as first-line treatment of European non-small-cell lung cancer (NSCLC) patients (pts.) with epidermal growth factor receptor (EGFR) activating mutations (mut+)

✍ Petruzelka, Lubos 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Detection of EGFR and KRAS mutations in

Detection of EGFR and KRAS mutations in circulating free DNA in patients with operable non small cell lung cancer (NSCLC)

✍ Board, R.; Shah, R.; Priest, L.; Bishop, P.; Ranson, M.; Hughes, A.N.; Dive, C.; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Clinical outcomes in non-small-cell lung

Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis

✍ Luis Paz-Ares; Denis Soulières; Ivan Melezínek; Joachim Moecks; Lorenz Keil; Ton 📂 Article 📅 2010 🏛 Carol Davila University of Medicine Bucharest, Rom 🌐 English ⚖ 746 KB

A novel EGFR nonsense mutation in a non-

A novel EGFR nonsense mutation in a non-small-cell lung cancer (NSCLC) patient who did not derive any clinical benefit with combination chemotherapy and erlotinib

✍ Ramón González Manzano; Elena Martínez Navarro; Elena Eugenieva; Francisco José 📂 Article 📅 2008 🏛 Springer Milan 🌐 Spanish ⚖ 276 KB